5 Key Initiatives Pushing The European Clinical Trial Market Forward

In the last year, there has been a wave of changes made to the policies that govern the European life sciences industry. 

With only 22% of new global treatments originating in Europe - and nearly 50% being developed in the United States (1) - these new regulations are a concerted effort to increase the R&D attractiveness of Europe.  

Not only that, but these updates are making clear strides in increasing the accessibility of clinical research to patients across Europe, a model Curebase firmly stands by.

With so many recent shifts in regulation, we’ve compiled a brief overview below.

To learn more about Curebase, visit their Clinical Leader page.